Neuland Laboratories Q2: Profit falls 47%, revenue declines 12.5%; margins contract

Neuland Laboratories reported a 46.7% year-on-year decline in consolidated profit to ₹51.6 crore, while EBITDA margin contracted to 21.7% from 30.2% a year ago. The company cited a dip in quarterly performance but retained its FY27 growth expectations.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Neuland Laboratories (NEULANDLAB).
- Category: Orders & Deals.
Why it matters
A routine update for Neuland Laboratories. Use the price and stock snapshot to gauge how the market is responding.
















